| Name | Title | Contact Details |
|---|
AmerisourceBergen (NYSE: ABC) is one of the world`s largest pharmaceutical sourcing and distribution services companies, working alongside healthcare providers and pharmaceutical manufacturers to improve access to products and enhance patient care. With services ranging from drug distribution and supply chain management to patient support solutions and pharmaceutical commercialization, AmerisourceBergen enables quality care and innovation in human and animal health. Tens of thousands of pharmacies, physician practices, health systems, veterinary practices, livestock producers and pharmaceutical manufacturers turn to AmerisourceBergen for the expertise they need to drive business performance. With more than $135 billion in annual revenue and 18,000 global associates, AmerisourceBergen is ranked #12 on the Fortune 500 and #1 on the Barron`s 500. The company is headquartered in Valley Forge, Pa., with a network of 140+ offices in 50+ countries.
Wisteria Cottage is a Sequim, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Recuro is a leading virtual-first care delivery company offering a personalized, holistic, and proactive approach to healthcare, looking to make advanced healthcare more accessible. Recuro provides seamless access to various virtual care services, including primary and urgent care, behavioral health, at-home lab testing, and genomics testing. Additionally, Recuro provides a comprehensive suite of supplemental benefits, integrated prescriptions, care management, and care navigation, all available on a unified platform.
Dental Health Associates is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Dental Health Associates is based in Phillipsburg, NJ. You can find more information on Dental Health Associates at www.njdha.com
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.